TY - JOUR
T1 - Effect of HIFU treatment on tumor targeting efficacy of docetaxel-loaded Pluronic nanoparticles
AU - Oh, Keun Sang
AU - Han, Hyounkoo
AU - Yoon, Byeong Deok
AU - Lee, Minae
AU - Kim, Hyuncheol
AU - Seo, Dong Wan
AU - Seo, Jae Hong
AU - Kim, Kwang Meyung
AU - Kwon, Ick Chan
AU - Yuk, Soon Hong
PY - 2014/7/1
Y1 - 2014/7/1
N2 - Numerous studies have been performed to identify the microenvironment of solid tumors, which is responsible for the insufficient delivery of anticancer drugs to tumor cells due to the poorly organized vasculature and the increased interstitial fluid pressure. As a result, the extravasation of convection-dependent agents including NPs is severely limited. Therefore, we have demonstrated the feasibility of targeting an enhancement of docetaxel-loaded Pluronic nanoparticles (NPs) using high-intensity focused ultrasound (HIFU) as an external stimulus-induced clinical system in tumor tissue. The efficient extravasation of NPs into the interior cells in tumor tissue was induced by relatively low HIFU exposure without apparent acute tissue damage. The enhanced targeting of NPs with near-infrared fluorescence dye was observed in tumor-bearing mice with various HIFU exposures. As a result, the greatest accumulation of NPs at the tumor tissue was observed at an HIFU exposure of 20W/cm2. However, the tumor tissue above at 20W/cm2 appeared to be destroyed and the tumor targetability of NPs was significantly decreased owing to thermal ablation with necrosis, resulting in the destruction of the tumor tissue and the blood vessels. In particular, a cross-sectional view of the tumor tissue verified that the NPs migrated into the middle of the tumor tissue upon HIFU exposure. The preliminary results here demonstrate that HIFU exposure through non-thermal mechanisms can aid with the extravasation of NPs into the interior cells of tumors and increase the therapeutic effect in enhanced and targeted cancer therapy.
AB - Numerous studies have been performed to identify the microenvironment of solid tumors, which is responsible for the insufficient delivery of anticancer drugs to tumor cells due to the poorly organized vasculature and the increased interstitial fluid pressure. As a result, the extravasation of convection-dependent agents including NPs is severely limited. Therefore, we have demonstrated the feasibility of targeting an enhancement of docetaxel-loaded Pluronic nanoparticles (NPs) using high-intensity focused ultrasound (HIFU) as an external stimulus-induced clinical system in tumor tissue. The efficient extravasation of NPs into the interior cells in tumor tissue was induced by relatively low HIFU exposure without apparent acute tissue damage. The enhanced targeting of NPs with near-infrared fluorescence dye was observed in tumor-bearing mice with various HIFU exposures. As a result, the greatest accumulation of NPs at the tumor tissue was observed at an HIFU exposure of 20W/cm2. However, the tumor tissue above at 20W/cm2 appeared to be destroyed and the tumor targetability of NPs was significantly decreased owing to thermal ablation with necrosis, resulting in the destruction of the tumor tissue and the blood vessels. In particular, a cross-sectional view of the tumor tissue verified that the NPs migrated into the middle of the tumor tissue upon HIFU exposure. The preliminary results here demonstrate that HIFU exposure through non-thermal mechanisms can aid with the extravasation of NPs into the interior cells of tumors and increase the therapeutic effect in enhanced and targeted cancer therapy.
KW - Effective cancer therapy
KW - Extravasation
KW - Pluronic nanoparticles
KW - Targeting enhancement
KW - Ultrasound-induced
UR - http://www.scopus.com/inward/record.url?scp=84902388507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902388507&partnerID=8YFLogxK
U2 - 10.1016/j.colsurfb.2014.05.007
DO - 10.1016/j.colsurfb.2014.05.007
M3 - Article
C2 - 24881526
AN - SCOPUS:84902388507
VL - 119
SP - 137
EP - 144
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
SN - 0927-7765
ER -